Universe Pharmaceuticals Inc.
UPC · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.02 | 0.01 | 0.06 |
| FCF Yield | -1,109.37% | 31.87% | -11.67% | -33.25% |
| EV / EBITDA | 2.80 | -1.11 | -1.61 | 3.04 |
| Quality | ||||
| ROIC | -16.11% | -12.43% | -15.25% | 17.78% |
| Gross Margin | 26.37% | 31.93% | 54.53% | 52.78% |
| Cash Conversion Ratio | 1.09 | -0.17 | 0.17 | -0.18 |
| Growth | ||||
| Revenue 3-Year CAGR | -16.91% | -12.35% | 9.35% | 13.03% |
| Free Cash Flow Growth | -1,017.34% | 176.52% | 90.98% | -357.07% |
| Safety | ||||
| Net Debt / EBITDA | 2.92 | -0.06 | 0.28 | -0.26 |
| Interest Coverage | -28.83 | -22.49 | -43.22 | 133.76 |
| Efficiency | ||||
| Inventory Turnover | 9.76 | 6.58 | 8.27 | 9.20 |
| Cash Conversion Cycle | 214.98 | 120.81 | 120.68 | 74.39 |